Bluebird taps Gritstone for oncology cell therapy targets

Bluebird bio has teamed up with Gritstone Oncology to access another set of targets for its oncology cell therapies. The deal sees bluebird pay $20 million upfront in return for 10 tumor-specific targets and T-cell receptors (TCRs).